A 2026 review in Expert Opinion on Drug Delivery consolidates the current state of semaglutide therapy and its formulation science. Subcutaneous semaglutide achieves near-complete systemic exposure, whereas the approved oral tablet reaches only approximately 0.8% absolute bioavailability. Emerging strategies including nanoparticle carriers, ionic-liquid formulations, and extracellular-vesicle delivery are advancing to close that gap.
What Structural Features of Semaglutide Govern Its Pharmacokinetics?
Semaglutide is a GLP-1 analogue modified at two positions. An Aib substitution at position 8 blocks DPP-4 cleavage, and a C-18 fatty diacid chain attached via a linker to Lys26 drives high-affinity albumin binding. Together these modifications extend the plasma half-life to approximately 165 to 185 hours for the oral form, enabling once-weekly subcutaneous or once-daily oral dosing.
The 94% structural homology with native GLP-1 is preserved at the receptor-binding domain, maintaining full agonist activity at the GLP-1 receptor. Albumin binding retards renal filtration and shields the peptide backbone from circulating proteases. The linker chemistry uses a hydrophilic mini-PEG spacer that reduces steric interference with receptor engagement while still allowing reversible albumin association.
These structural choices create a pharmacokinetic profile that is largely route-independent for the subcutaneous form but becomes highly sensitive to gastrointestinal conditions for the oral form. Gastric pH, food content, and mucosal transit time each introduce variability that the SNAC co-formulation only partially resolves.
How Does the SNAC Absorption Enhancer Work in the Oral Tablet?
Salcaprozate sodium (SNAC) acts as a localised gastric buffer and membrane permeation enhancer. As the tablet erodes, SNAC raises the microenvironmental pH around the dissolving semaglutide, suppressing pepsin activity and reducing acid-catalysed degradation. It simultaneously increases transcellular permeability of the gastric epithelium, enabling direct gastric absorption rather than intestinal uptake.
The mechanism is spatially restricted to within millimetres of the dissolving tablet surface, not distributed across the gastric lumen. This localisation avoids systemic pH disruption while the peptide is transiently protected. Absorption occurs predominantly in the stomach, which is why the approved dosing protocol mandates administration with no more than 120 mL of water and a 30-minute pre-meal fasting window.
Despite this engineering, absolute oral bioavailability remains approximately 0.8% under recommended conditions. Inter-individual variability is substantial, and food co-administration reduces exposure by up to 50%. The SNAC approach therefore represents a proof-of-concept for gastric peptide absorption rather than a fully optimised delivery solution.
What Is the Quantitative Bioavailability Gap Between Oral and Subcutaneous Semaglutide?
Subcutaneous semaglutide achieves approximately 89% absolute bioavailability. The oral tablet achieves roughly 0.4 to 1% under real-world conditions. This approximately 100-fold disparity necessitates the oral dose being 10 to 20 times higher on a milligram basis to achieve comparable receptor occupancy.
The clinical consequence of this disparity extends beyond dose escalation. Higher oral doses increase the probability of gastrointestinal adverse events such as nausea, vomiting, and diarrhoea. The variability introduced by food, gastric emptying rate, and co-medications further complicates titration in clinical practice.
Pharmacokinetic modelling from the PIONEER programme demonstrates that even at 14 mg daily, oral semaglutide produces HbA1c reductions and weight loss numerically comparable to subcutaneous 0.5 mg weekly. This confirms that sufficient systemic exposure is achievable, but at the cost of formulation complexity and patient adherence burden.
What Emerging Delivery Strategies Are Being Investigated to Improve Semaglutide Bioavailability?
Three delivery platforms dominate the 2025 to 2026 preclinical literature: lipid-based nanoparticles, ionic-liquid formulations, and milk-derived small extracellular vesicles (sEVs). Each addresses a distinct barrier such as enzymatic degradation, membrane permeability, or mucosal transit. Preliminary data suggest bioavailability improvements of 2 to 8-fold over the SNAC tablet in rodent models.
Sodium glycocholate liposome-encapsulated semaglutide has demonstrated enhanced intestinal permeability and extended blood circulation time in preclinical studies. The bile-salt surfactant component disrupts tight junctions transiently, facilitating paracellular transport, while the lipid shell protects the peptide from luminal proteases. Liposomal formulations also permit enteric coating, shifting absorption from the stomach to the small intestine where surface area is orders of magnitude greater.
Ionic-liquid based enteric systems can solubilise hydrophilic peptides within a hydrophobic matrix, improving membrane partitioning. An IL-based enteric formulation for semaglutide reported in 2024 showed reduced gastric degradation and enhanced jejunal absorption in a rat model. Human pharmacokinetic data for IL-based semaglutide formulations remain absent from the published literature.
Milk-derived sEVs are the most biologically novel vector under investigation. A 2024 preprint demonstrated that bovine milk exosomes loaded with semaglutide survived gastric transit and were taken up by intestinal epithelial cells via endocytosis. The authors reported oral bioavailability of approximately 5% in mice, a roughly 6-fold improvement over the SNAC formulation, though translation to human gastrointestinal physiology requires validation.
What Are the Current Therapeutic Trends Shaping Semaglutide's Clinical Use in 2026?
Semaglutide's clinical footprint has expanded well beyond glycaemic control. The SELECT trial established a 20% MACE reduction in non-diabetic obese patients. The FLOW trial demonstrated slowed CKD progression in high-risk type 2 diabetes. The SOUL trial confirmed oral semaglutide reduces MACE by approximately 14% in patients with established cardiovascular or renal disease.
These outcomes have repositioned semaglutide from a glucose-lowering agent to a cardiometabolic disease-modifying therapy. The mechanistic basis for cardiovascular benefit likely involves direct GLP-1R signalling in cardiac and vascular tissue, anti-inflammatory effects mediated through reduced adiposity, and improvements in endothelial function independent of weight loss.
Renal protection appears to involve GLP-1R-mediated reduction in glomerular hyperfiltration, attenuation of tubular inflammation, and indirect effects through blood pressure and weight reduction. The FLOW trial reported a 24% reduction in the composite kidney endpoint with once-weekly subcutaneous semaglutide 1.0 mg versus placebo.
Emerging indications under active investigation include metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnoea, polycystic ovary syndrome, and Alzheimer's disease. The breadth of these programmes reflects the pleiotropic distribution of GLP-1R expression across hepatic, pulmonary, ovarian, and neural tissue.
What Formulation and Regulatory Challenges Remain for Next-Generation Oral Semaglutide?
Translating preclinical bioavailability gains into approved products requires demonstrating not only improved exposure but also dose-proportionality, acceptable variability, and a safety profile for the excipient system itself. Regulatory agencies require that absorption enhancers used at therapeutic concentrations do not cause sustained mucosal damage, a bar that has historically limited permeation enhancer development.
Nanoparticle and vesicle-based carriers introduce additional regulatory complexity around characterisation of particle size distribution, batch-to-batch consistency, and long-term stability. The FDA's guidance on complex drug substances requires physicochemical equivalence data that are technically demanding for lipid-based systems. Manufacturing scale-up of exosome-based formulations remains a significant unresolved challenge.
Patient-level factors compound formulation challenges. Gastric emptying rate varies substantially with age, diabetes duration, and concomitant medications including other GLP-1 agonists and anticholinergics. A formulation optimised for average gastric transit may perform poorly in patients with gastroparesis, a population that overlaps significantly with advanced type 2 diabetes.
How Should Clinicians and Researchers Evaluate the Evidence Quality for These Strategies?
The cardiovascular and renal outcome data for semaglutide rest on large, well-powered RCTs including SELECT (n=17,604), FLOW (n=3,533), and SOUL (n=9,650), representing the highest tier of clinical evidence. By contrast, all novel bioavailability-enhancement strategies remain at the preclinical stage, with no completed Phase 1 human pharmacokinetic trials published as of mid-2026.
The 2026 Expert Opinion on Drug Delivery review synthesises this landscape, noting that the gap between preclinical bioavailability data and clinical translation has historically been wide for oral peptide delivery. Rodent gastrointestinal anatomy, transit time, and mucosal enzyme activity differ substantially from humans, limiting the predictive validity of mouse and rat bioavailability figures.
Researchers evaluating this literature should apply standard preclinical-to-clinical attrition expectations. Fewer than 10% of novel oral peptide delivery systems that show promising rodent data have successfully completed Phase 2 trials. The SNAC-semaglutide system remains the only approved oral GLP-1 agonist globally, and its modest absolute bioavailability underscores the difficulty of the problem.